Founded in 2019 and headquartered in Shanghai, China, GRIT Biotechnology is committed to improving the treatment of solid tumors by developing and researching Tumor Infiltration Lymphocytes (TIL) immunotherapy. The company's innovative approach to cancer treatment involves extracting TILs from a patient's tumor, growing them in a lab, and then infusing them back into the patient's body to attack the cancer cells. By leveraging the body's natural immune system, GRIT Biotechnology's immunotherapy offers a promising alternative to traditional cancer treatments.